Previous 10 | Next 10 |
- Partnership leverages Theramex’s leading women’s health capabilities and commercial infrastructure to support the commercialization and market introduction of linzagolix across global markets outside of the U.S., Canada and Asia - - Linzagolix is an oral GnRH ant...
ObsEva (NASDAQ:OBSV) is trading ~5% lower in the post-market on Friday after the company announced that its European marketing authorization for linzagolix could extend. Linzagolix is a once-daily, oral GnRH receptor antagonist which has undergone late-stage trials for uterine fibro...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 4 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women ...
Buying Penny Stocks Today? Here’s What You Need to Know With the month of February here for trading penny stocks and blue chips, there is a lot for investors to consider. Now, January was a tough month in the stock market without a doubt. Data shows that January was the worst per...
ObsEva (NASDAQ:OBSV) is trading ~7% higher in the pre-market on above-average volume after announcing the appointment of Katja Buhrer as its Chief Strategy Officer and member of the company’s Executive Committee effective Feb. 01. About 3.7M company shares have changed hands ...
AMC Entertainment Holdings (NYSE:AMC) +14% as preliminary Q4 revenue tops consensus. Wallbox (NYSE:WBX) +14% Uber and Wallbox to expand partnership to all of the U.S. Spire Global (NYSE:SPIR) +10% as preliminary Q4 revenue soars 111% Y/Y. ObsEva (NASDAQ:OBSV) +9%. ProQR Th...
GENEVA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the appointment of Katja Buhrer as Chief Strategy Officer and member of the company’...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – January 28, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The year 2021 will be remembered for price-action among penny stocks and meme stocks. On a relative basis, the penny stock investing euphoria has declined. However, that does not imply absence of good short- to medium-term ...
-Once daily linzagolix 200 mg with ABT met both co-primary efficacy objectives, demonstrating reductions in dysmenorrhea and non-menstrual pelvic pain versus placebo at 3 months; showed statistically significant and clinically meaningful improvements versus placebo in ranked secondary end...
News, Short Squeeze, Breakout and More Instantly...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that the Regulatory ...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that, concurr...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it will wind-down its operati...